Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Eriksson, T. He, A. Trejo-Skalli, A. Härmälä-Braskén, J. Hellman, Y. Chou, R. Goldman (2004)
Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filamentsJournal of Cell Science, 117
Thorsten Hagemann, B. Gunawan, Matthias Schulz, L. Füzesi, Claudia Binder (2001)
mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas.European journal of cancer, 37 15
B. Kallakury, S. Karikehalli, A. Haholu, Christine Sheehan, N. Azumi, J. Ross (2001)
Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 10
N. Kamiya, T. Kishimoto, Hiroyoshi Suzuki, N. Sekita, Y. Nagai, Nobuyuki Oosumi, Hiroki Kito, N. Tochigi, M. Shinbo, R. Nemori, T. Ichikawa, T. Igarashi, Haruo Ito, H. Ishikura (2003)
Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasionInternational Journal of Cancer, 106
Y. Kitagawa, K. Kunimi, T. Uchibayashi, Hiroshi Sato, M. Namiki (1999)
Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas.The Journal of urology, 162 3 Pt 1
Salomón Matías-Román, B. Galvez, L. Genı́s, M. Yáñez‐Mó, Gonzalo Rosa, P. Sánchez-Mateos, F. Sánchez‐Madrid, A. Arroyo (2005)
Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium.Blood, 105 10
V. Golubkov, A. Strongin (2007)
Proteolysis-Driven OncogenesisCell Cycle, 6
B. Petrella, J. Lohi, C. Brinckerhoff (2005)
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinomaOncogene, 24
Xing Wang, D. Ma, J. Keski‐oja, D. Pei (2004)
Co-recycling of MT1-MMP and MT3-MMP through the Trans-Golgi NetworkJournal of Biological Chemistry, 279
V. Golubkov, S. Boyd, A. Savinov, Alexei Chekanov, A. Osterman, A. Remacle, D. Rozanov, S. Doxsey, A. Strongin (2005)
Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Exhibits an Important Intracellular Cleavage Function and Causes Chromosome Instability*Journal of Biological Chemistry, 280
L. Barberis, C. Pasquali, Dominique Bertschy-Meier, A. Cuccurullo, C. Costa, C. Ambrogio, F. Vilbois, R. Chiarle, M. Wymann, F. Altruda, C. Rommel, E. Hirsch (2009)
Leukocyte transmigration is modulated by chemokine‐mediated PI3Kγ‐dependent phosphorylation of vimentinEuropean Journal of Immunology, 39
F. Fritzsche, K. Wassermann, M. Jung, A. Tölle, Ilka Kristiansen, M. Lein, M. Johannsen, M. Dietel, K. Jung, G. Kristiansen (2008)
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progressionBMC Cancer, 8
H. Oka, Y. Chatani, R. Hoshino, Osamu Ogawa, Y. Kakehi, T. Terachi, Yûsaku Okada, M. Kawaichi, M. Kohno, O. Yoshida (1995)
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.Cancer research, 55 18
C. Berthier, P. Wahl, M. Hir, H. Marti, U. Wagner, H. Rehrauer, R. Wüthrich, A. Serra (2007)
Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 23 3
P. Clark (2009)
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.Kidney international, 76 9
K. Hotary, E. Allen, A. Punturieri, I. Yana, S. Weiss (2000)
Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3The Journal of Cell Biology, 149
D. Lovett, Sunfa Cheng, L. Cape, A. Pollock, P. Mertens (2010)
YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis.Biochemical and biophysical research communications, 398 3
R. Montesano, J. Soriano, Ghamartaj Hosseini, M. Pepper, Herbert Schramek (1999)
Constitutively active mitogen-activated protein kinase kinase MEK1 disrupts morphogenesis and induces an invasive phenotype in Madin-Darby canine kidney epithelial cells.Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 10 5
J. Bravo-Cordero, R. Marrero-Diaz, D. Megías, L. Genı́s, Aránzazu García-Grande, María García, A. Arroyo, M. Montoya (2007)
MT1‐MMP proinvasive activity is regulated by a novel Rab8‐dependent exocytic pathwayThe EMBO Journal, 26
Jian Cao, Pallavi Kozarekar, M. Pavlaki, Christian Chiarelli, W. Bahou, S. Zucker (2004)
Distinct Roles for the Catalytic and Hemopexin Domains of Membrane Type 1-Matrix Metalloproteinase in Substrate Degradation and Cell Migration*Journal of Biological Chemistry, 279
J. Dancey (2010)
mTOR signaling and drug development in cancerNature Reviews Clinical Oncology, 7
R. Hoshino, Y. Chatani, T. Yamori, T. Tsuruo, H. Oka, O. Yoshida, Y. Shimada, Shigeki Ari-i, H. Wada, J. Fujimoto, M. Kohno (1999)
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumorsOncogene, 18
Jian Cao, Christian Chiarelli, O. Richman, K. Zarrabi, Pallavi Kozarekar, S. Zucker (2008)
Membrane Type 1 Matrix Metalloproteinase Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer*Journal of Biological Chemistry, 283
S. D'Alessio, G. Ferrari, Karma Cinnante, W. Scheerer, A. Galloway, D. Roses, D. Rozanov, A. Remacle, E. Oh, S. Shiryaev, A. Strongin, G. Pintucci, P. Mignatti (2008)
Tissue Inhibitor of Metalloproteinases-2 Binding to Membrane-type 1 Matrix Metalloproteinase Induces MAPK Activation and Cell Growth by a Non-proteolytic Mechanism*Journal of Biological Chemistry, 283
Dan Huang, Yan Ding, W. Luo, S. Bender, C. Qian, E. Kort, Zhong-Fa Zhang, K. Vandenbeldt, N. Duesbery, J. Resau, B. Teh (2008)
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.Cancer research, 68 1
N. Nakaigawa, M. Yao, M. Baba, S. Kato, T. Kishida, K. Hattori, Y. Nagashima, Y. Kubota (2006)
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.Cancer research, 66 7
Y. Itoh, M. Seiki (2006)
MT1‐MMP: A potent modifier of pericellular microenvironmentJournal of Cellular Physiology, 206
L. Gunaratnam, M. Morley, A. Franovic, N. Paulsen, Karim Mekhail, D. Parolin, E. Nakamura, I. Lorimer, Stephen Lee (2003)
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells*Journal of Biological Chemistry, 278
V. Golubkov, Alexey Chekanov, A. Savinov, D. Rozanov, Natalya Golubkova, A. Strongin (2006)
Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells.Cancer research, 66 21
N. Sounni, D. Rozanov, A. Remacle, V. Golubkov, A. Noel, A. Strongin (2009)
Timp‐2 binding with cellular MT1‐MMP stimulates invasion‐promoting MEK/ERK signaling in cancer cellsInternational Journal of Cancer, 126
Pamela Boyd, Jennifer Doyle, Eric Gee, Shelley Pallan, T. Haas (2005)
MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2.American journal of physiology. Cell physiology, 288 3
L. Gossage, T. Eisen (2010)
Alterations in VHL as potential biomarkers in renal-cell carcinomaNature Reviews Clinical Oncology, 7
A. Morotti, S. Mila, P. Accornero, Emmanuelle Tagliabue, C. Ponzetto (2002)
K252a inhibits the oncogenic properties of Met, the HGF receptorOncogene, 21
S. Langlois, C. Nyalendo, Geneviève Tomasso, L. Labrecque, C. Roghi, G. Murphy, D. Gingras, R. Béliveau (2007)
Membrane-Type 1 Matrix Metalloproteinase Stimulates Cell Migration through Epidermal Growth Factor Receptor TransactivationMolecular Cancer Research, 5
J. Bradley, M. Kelley, A. Rose, T. Acott (2003)
Signaling pathways used in trabecular matrix metalloproteinase response to mechanical stretch.Investigative ophthalmology & visual science, 44 12
M. Seiki, I. Yana (2003)
Roles of pericellular proteolysis by membrane type‐1 matrix metalloproteinase in cancer invasion and angiogenesisCancer Science, 94
S. Cockerill, C. Stubberfield, J. Stables, M. Carter, S. Guntrip, K. Smith, S. McKeown, R. Shaw, P. Topley, L. Thomsen, K. Affleck, A. Jowett, D. Hayes, M. Willson, P. Woollard, D. Spalding (2001)
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.Bioorganic & medicinal chemistry letters, 11 11
B. Petrella, C. Brinckerhoff (2006)
Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinaseMolecular Cancer, 5
S. Lee, J. Lattouf, J. Xanthopoulos, W. Linehan, D. Bottaro, J. Vasselli (2008)
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.European urology, 54 4
P. Soulié, F. Carrozzino, M. Pepper, A. Strongin, M. Poupon, R. Montesano (2005)
Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cellsOncogene, 24
Nazeel Ahmad, Connie Keehn, D. Coppola (2004)
The expression of insulin-like growth factor-I receptor correlates with Fuhrman grading of renal cell carcinomas.Human pathology, 35 9
Activation of Raf/Ras/mitogen-activated protein kinase (MEK)/mitogen-activated protein kinase signaling and elevated expression of membrane type-1 matrix metalloproteinase (MT1-MMP) are associated with von HippelLindau gene alterations in renal cell carcinoma. We postulated that the degree of MEK activation was related to graded expression of MT1-MMP and the resultant phenotype of renal epithelial tumors. Madin Darby canine kidney epithelial cells transfected with a MEK1 expression plasmid yielded populations with morphologic phenotypes ranging from epithelial, mixed epithelial/mesenchymal to mesenchymal. Clones were analyzed for MEK1 activity, MT1-MMP expression and extent of epithelialmesenchymal transition. Phenotypes of the MDCK-MEK1 clones were evaluated in vivo with nu/nu mice. Tissue microarray of renal cell cancers was quantitatively assessed for expression of phosphorylated MEK1 and MT1-MMP proteins and correlations drawn to Fuhrman nuclear grade. Graded increases in the MEK signaling module were associated with graded induction of epithelialmesenchymal transition of the MDCK cells and induction of MT1-MMP transcription and synthesis. Inhibition of MEK1 and MT1-MMP activity reversed the epithelialmesenchymal transition. Tumors generated by epithelial, mixed epithelial/mesenchymal and mesenchymal MDCK clones demonstrated a gradient of phenotypes extending from well-differentiated, fully encapsulated non-invasive tumors to tumors with an anaplastic morphology, high Fuhrman nuclear score, neoangiogenesis and invasion. Tumor microarray demonstrated a statistically significant association between the extent of phosphorylated MEK1, MT1-MMP expression and nuclear grade. We conclude that graded increases in the MEK1 signaling module are correlated with M1-MMP expression, renal epithelial cell tumor phenotype, invasive activity and nuclear grade. Phosphorylated MEK1 and MT1-MMP may represent novel, and mechanistic, biomarkers for the assessment of renal cell carcinoma.
Carcinogenesis – Oxford University Press
Published: Dec 28, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.